

## **Midven Leads £1.25m First Round for Cyttox**

*Unquote – April 2007*

### **Investors**

Midven has led the first institutional round of funding for Cyttox Ltd, a biotechnology company developing a diagnostic test to facilitate the early identification of Alzheimer's disease. NESTA also contributed to the round along with a group of angel investors. NESTA introduced Midven to the deal, which invested through its Advantage Growth Fund.

The technology appealed to Midven as currently there is no method of diagnosing the condition before the symptoms of dementia start to occur. An ageing population means that the number of people suffering from the condition is expected to rise, making Cyttox's testing technology even more important.

### **Company**

Based in Birmingham, Cyttox is a spinout from the University of Oxford and builds on the research developed by Dr Zsuzsanna Nagy while at Oxford. This research has identified a link between the development of Alzheimer's disease and cell cycle abnormalities. The ambition of Cyttox is to develop a simple blood test to predict a person's likeliness of developing Alzheimer's. Cyttox will use the investment to continue the research, work towards clinical testing and build a commercial management team. Cyttox currently employs four staff.